Experience History
Board of Directors Member CytImmune Sciences October 2013 – Present (3 years 5 months)
CytImmune Sciences is a clinical stage nanomedicine company with a core focus on the discovery, development and commercialization of multifunctional, tumor-targeted therapies. Based on an R&D strategy which harnesses the unique properties of gold nanoparticles, cytotoxic agents, and biology of tumors, the Company is developing a pipeline of proprietary drug candidates binding potent anti-cancer agents -- whose toxicity profiles currently prevent or severely limit clinical use -- to its patented colloidal gold tumor-targeting nanotechnology.
Board of Directors Member Jenrin Discovery July 2012 – Present (4 years 8 months)
Jenrin Discovery is a privately held company developing a pipeline of proprietary ‘first-in-class’ small molecule drugs designed to selectively target peripheral tissues. Jenrin applies its technology and medicinal chemistry expertise to structurally modify specific drugs so as to prevent penetration across the blood-brain barrier, resulting in negligible or no brain levels of drug. The Jenrin strategy of ‘rational drug re-design’ capitalizes on years of medicinal chemistry that were used to optimize the original drug, significantly shortening discovery timelines and lowering development risk. Development activities have focused on targeted programs, including metabolic disorders, inflammation/pain, and infectious diseases.
MYOS Corporation Chief Medical Officer January 2014 – January 2016 (2 years 1 month)
MYOS is a developmental stage bionutrition and biotherapeutics company focused on the discovery, development and commercialization of products that improve muscle health and function essential to the management of sarcopenia, cachexia and degenerative muscle diseases. MYOS is the owner of MYO-T12®, the first clinically proven natural myostatin inhibitor. Myostatin is a natural regulatory protein, which inhibits muscle growth and recovery. Medical literature suggests that lowering myostatin levels has many potential health benefits including increased muscle mass, healthy weight management, improved energy levels, stimulation of muscle healing as well as treating sarcopenia, a condition of age-related loss of muscle mass.
Advanced Practice Strategies (APS) Chief Medical Officer April 2012 – January 2014 (1 year 10 months)Greater Boston Area
Advanced Practice Strategies (APS) is eliminating risk and reducing healthcare costs by making it easier for physicians, nurses, and other providers to fill knowledge gaps that lead to serious medical errors. The company’s newest innovation, GNOSIS, is a groundbreaking mobile, cloud-based tool that assesses clinician proficiency by creating a mathematical representation of clinical decision making scripts, uses that model to map latent risk, and delivers highly customized education that saves clinician learning time, rapidly improves performance, reduces medical malpractice risk, and increases patient safety, all while ensuring administrators are equipped with a transparent performance dashboard at the clinician, organization, and system-wide levels. GNOSIS redefines continuing clinical education while addressing healthcare quality, costs, and satisfaction in today’s accountable medical world.
Montefiore Medical Center Thoracic Surgeon March 2009 – April 2012 (3 years 2 months)
Director of Minimally Invasive Thoracic Surgery
MDLinx Founder 2000 – 2006 (6 years)Greater New York City Area
Co-founder of MDLinx, Inc., an online healthcare media company, that was acquired by SONY (So-Net M3, a Sony Communication Network Group Company) in 2006. *MDLinx business units include advertising, market research, content licensing, and e-detailing.
*
Columbia University Medical Center Thoracic Surgery Resident July 1998 – June 2000 (2 years)
view the rest of the comments →
Littleredcorvette ago
Here is a little information about the last doctor. I was curious to see what his specialties were. I pulled this info from LinkedIn.
Robert C Ashton, Jr MD Ashton’s specialties included Thoracic Surgery. He is affiliated with Children’s Hospital at Montefiore Medical Center. Here is his LinkedIn Page. https://www.linkedin.com/in/robert-ashton-md-100b0833 http://archive.is/pDALz
Experience History Board of Directors Member CytImmune Sciences October 2013 – Present (3 years 5 months)
CytImmune Sciences is a clinical stage nanomedicine company with a core focus on the discovery, development and commercialization of multifunctional, tumor-targeted therapies. Based on an R&D strategy which harnesses the unique properties of gold nanoparticles, cytotoxic agents, and biology of tumors, the Company is developing a pipeline of proprietary drug candidates binding potent anti-cancer agents -- whose toxicity profiles currently prevent or severely limit clinical use -- to its patented colloidal gold tumor-targeting nanotechnology.
Board of Directors Member Jenrin Discovery July 2012 – Present (4 years 8 months) Jenrin Discovery is a privately held company developing a pipeline of proprietary ‘first-in-class’ small molecule drugs designed to selectively target peripheral tissues. Jenrin applies its technology and medicinal chemistry expertise to structurally modify specific drugs so as to prevent penetration across the blood-brain barrier, resulting in negligible or no brain levels of drug. The Jenrin strategy of ‘rational drug re-design’ capitalizes on years of medicinal chemistry that were used to optimize the original drug, significantly shortening discovery timelines and lowering development risk. Development activities have focused on targeted programs, including metabolic disorders, inflammation/pain, and infectious diseases.
MYOS Corporation Chief Medical Officer January 2014 – January 2016 (2 years 1 month) MYOS is a developmental stage bionutrition and biotherapeutics company focused on the discovery, development and commercialization of products that improve muscle health and function essential to the management of sarcopenia, cachexia and degenerative muscle diseases. MYOS is the owner of MYO-T12®, the first clinically proven natural myostatin inhibitor. Myostatin is a natural regulatory protein, which inhibits muscle growth and recovery. Medical literature suggests that lowering myostatin levels has many potential health benefits including increased muscle mass, healthy weight management, improved energy levels, stimulation of muscle healing as well as treating sarcopenia, a condition of age-related loss of muscle mass.
Advanced Practice Strategies (APS) Chief Medical Officer April 2012 – January 2014 (1 year 10 months)Greater Boston Area
Advanced Practice Strategies (APS) is eliminating risk and reducing healthcare costs by making it easier for physicians, nurses, and other providers to fill knowledge gaps that lead to serious medical errors. The company’s newest innovation, GNOSIS, is a groundbreaking mobile, cloud-based tool that assesses clinician proficiency by creating a mathematical representation of clinical decision making scripts, uses that model to map latent risk, and delivers highly customized education that saves clinician learning time, rapidly improves performance, reduces medical malpractice risk, and increases patient safety, all while ensuring administrators are equipped with a transparent performance dashboard at the clinician, organization, and system-wide levels. GNOSIS redefines continuing clinical education while addressing healthcare quality, costs, and satisfaction in today’s accountable medical world.
Montefiore Medical Center Thoracic Surgeon March 2009 – April 2012 (3 years 2 months) Director of Minimally Invasive Thoracic Surgery
MDLinx Founder 2000 – 2006 (6 years)Greater New York City Area Co-founder of MDLinx, Inc., an online healthcare media company, that was acquired by SONY (So-Net M3, a Sony Communication Network Group Company) in 2006. *MDLinx business units include advertising, market research, content licensing, and e-detailing. * Columbia University Medical Center Thoracic Surgery Resident July 1998 – June 2000 (2 years)
cantsleepawink ago
Google CytImmune with Clinton. You'll find a few hits. Same conventions and so on. Can't see a direct link though.